MET and osteosarcoma: To explore the possibility of magnetic-driven hydrogel microrobots loaded with MET inhibitors in enhancing the efficacy of TKI targeted drugs against osteosarcoma, we have chosen SCR1481B1, a MET inhibitor, as the research drug.